title: Provision of opioid substitution therapy services in Australian pharmacies.
abstract: Opioid dependence, despite being the subject of significant public funding, remains a costly burden to Australian society in human and economic terms. The most cost-effective public health strategy for managing opioid dependence is opioid substitution therapy (OST), primarily through the use of methadone or buprenorphine. Supervised dispensing of OST from specialist clinics and community pharmacies plays a crucial role in enhancing compliance, monitoring treatment and reducing diversion. Australia, compared with other countries in the world, ranks very high in illicit opioid use; hence there is a great demand for OST.The utilisation of community pharmacies for stable patients has many advantages. For public clinics, patient transfer to community pharmacies relieves workload and costs, and increases capacity for new OST patients. From a patient's perspective, dosing at a pharmacy is more flexible and generally more preferable. Pharmacists stand to gain clientele, profit and receive small incentives from state governments in Australia, for their services. Yet, many "unmet needs" exist and there is a high demand for more involvement in OST service provision in community pharmacy in Australia.In the UK there has been a steady increase in community pharmacy provision of OST, and pharmacists appear ready to provide further healthcare services to these patients.The role of pharmacy in some countries in Europe, such as Germany, is less prominent due to their approach to harm minimisation and the complex, variable nature of OST provision across the European Union (EU). The provision of OST by pharmacists in the USA on the other hand is of lesser frequency as the healthcare system in the USA encourages detoxification clinics to handle cases of illicit drug addiction.At a time when harm minimisation strategies constitute a topic of considerable political and public interest, it is important to understand the scope and variability of pharmacy involvement in drug policy in Australia. Hence, this review highlights the role of pharmacists in OST and explores the scope for expanding this role in the future.
authors: The University of Sydney, Faculty of Pharmacy.
authors: B B
authors: BB
authors: Chaar
authors: J R
authors: JR
authors: Hanrahan
authors: C
authors: C
authors: Day
references: Med J Aust. 2007 Feb 5;186(3):152-3
references: 17309406
references: Drug Alcohol Rev. 2007 Jul;26(4):355-61
references: 17564870
references: Addiction. 1997 Dec;92(12):1737-48
references: 9581006
references: Drug Alcohol Rev. 2008 Jul;27(4):393-7
references: 18584389
references: BMJ. 1989 Oct 28;299(6707):1076-9
references: 2511969
references: BMJ. 1996 Aug 3;313(7052):272-4
references: 8704541
references: Addiction. 1999 Sep;94(9):1349-59
references: 10615720
references: Addiction. 2007 Nov;102(11):1824-30
references: 17935587
references: J Public Health (Oxf). 2007 Dec;29(4):350-7
references: 17986490
references: J Addict Dis. 2009;28(1):57-63
references: 19197596
references: Med J Aust. 2008 Apr 21;188(8):441-4
references: 18429708
references: Drug Alcohol Rev. 2008 Jan;27(1):47-53
references: 18034381
references: Int J Drug Policy. 2011 Jan;22(1):77-81
references: 20956077
references: Addiction. 2010 Feb;105(2):335-42
references: 20078490
references: Pharm World Sci. 2008 Dec;30(6):940-6
references: 18850299
references: Drug Alcohol Rev. 2007 Mar;26(2):143-51
references: 17364849
references: Int J Drug Policy. 2008 Dec;19(6):450-8
references: 18359216
references: Drug Alcohol Rev. 2007 Jul;26(4):411-6
references: 17564877
references: J Addict Dis. 2009 Jul;28(3):269-78
references: 20155596
references: Drug Alcohol Rev. 2004 Jun;23(2):195-202
references: 15370026